Long COVID Trial, Recruiting NCT04956445 Sponsor: Tulane University Condition: Long COVID
Back to Long Covid

Long COVID Trial, Recruiting

NCT04956445
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 (Initial enrolment):

  • People who have had a confirmed positive test for COVID-19, influenza A or B, a non-COVID coronavirus, parainfluenza virus, rhinovirus, adenovirus, or metapneumovirus
  • The person or their legal representative has given verbal agreement to participate and to the use of their health information

Group 2 (Follow-up participation):

  • People who either tested positive for COVID-19 more than 14 days ago, may have been exposed to COVID-19 and could have developed antibodies against it, OR have tested positive for influenza A or B, a non-COVID coronavirus, parainfluenza virus, rhinovirus, adenovirus, or metapneumovirus
  • The person or their legal representative has signed a written consent form to participate

Who may not be able to join: (These exclusions apply to Group 2 only)

  • Infants younger than 6 months of age
  • People with low red blood cell levels (a condition called anaemia, where haemoglobin is below a certain level) (confirm with trial site)
  • People with a low platelet count, which relates to the blood's ability to clot (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dahlene Fusco, MD, PhD, Tulane University School of Medicine

Phone: 504-988-7316

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tulane University
Registry
ClinicalTrials.gov
Start date
17 March 2020
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

COVID-19 clinically severe vs non severe cases; Post-COVID symptoms onset at 3 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov